Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bright Minds Biosciences Inc. - common stock
(NQ:
DRUG
)
49.79
-0.90 (-1.78%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bright Minds Biosciences Inc. - common stock
< Previous
1
2
3
4
5
Next >
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
October 16, 2024
Via
AB Newswire
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
↗
October 16, 2024
Via
Benzinga
Topics
Stocks
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
October 16, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
↗
October 16, 2024
Via
Benzinga
Bright Minds Biosciences Stock Surges Almost 1,500%
October 16, 2024
Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.
Via
MarketBeat
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
↗
October 15, 2024
Via
Benzinga
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
October 03, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
September 19, 2024
From
Bright Minds Biosciences
Via
GlobeNewswire
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
↗
August 16, 2024
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.
Via
Benzinga
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
↗
August 15, 2024
Bright Minds Biosciences just reported results for the third quarter of 2024.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
August 12, 2024
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
Via
InvestorPlace
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
↗
May 20, 2024
Bright Minds Biosciences just reported results for the second quarter of 2024.
Via
InvestorPlace
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
↗
April 17, 2024
Via
Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
↗
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
↗
March 20, 2024
Via
Benzinga
Topics
Economy
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
↗
March 04, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
↗
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
↗
February 15, 2024
Via
Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
↗
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
↗
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
↗
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
↗
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
↗
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
↗
December 11, 2023
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Via
Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
↗
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
↗
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
↗
November 12, 2023
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Via
Benzinga
Topics
Initial Public Offering
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
↗
November 06, 2023
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
Via
Benzinga
Topics
Economy
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
↗
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Via
Benzinga
Topics
Intellectual Property
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
↗
October 22, 2023
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
